A Korean Poly-Herbal Medicine, SMO16, Regulates the RANKL/OPG Bone Remodeling in OVX Rat Model
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Bone mass is regulated by bone resorption(osteoclast) and bone formation(osteoblast), and an imbalance between both processes results in osteoporosis. Osteoporosis is characterized by a loss of bone density and regulation of bone remodeling is crucial for the treatment of osteoporosis. In this study, we investigated whether SMO16, a Korean polyherbal medicine containing 5 herbal components, could regulate bone remodeling in an ovariectomized(OVX) rat model. To test the effect of SMO16 in the OVX model, the rats were divided into 3 groups: a control group, OVX group, and OVX + SMO16(2.25 g/kg) for 8 weeks(ST group). The expression of osteocalcin(OPC), receptor activator of nuclear factor kappa-B ligand(RANKL), and osteoprotegerin(OPG) were measured in the femur using specific antibodies. The bone mass was analyzed using dual-energy X-ray absorptiometry. In the OVX group, protein expression of OPC was decreased; however, in the ST group, OPC expression was significantly increased when compared with the OVX group. SMO16 significantly reduces RANKL-positive cells in the OVX rat femur. Additionally, SMO16 increased OPG expression levels. Importantly, SMO16 significantly increased bone density. These data suggest that SMO16 increases bone remodeling by regulating OPC, RANKL, and OPG signaling. SMO16 could be a potential alternative treatment for osteoporosis.
Abstract
Bone mass is regulated by bone resorption(osteoclast) and bone formation(osteoblast), and an imbalance between both processes results in osteoporosis. Osteoporosis is characterized by a loss of bone density and regulation of bone remodeling is crucial for the treatment of osteoporosis. In this study, we investigated whether SMO16, a Korean polyherbal medicine containing 5 herbal components, could regulate bone remodeling in an ovariectomized(OVX) rat model. To test the effect of SMO16 in the OVX model, the rats were divided into 3 groups: a control group, OVX group, and OVX + SMO16(2.25 g/kg) for 8 weeks(ST group). The expression of osteocalcin(OPC), receptor activator of nuclear factor kappa-B ligand(RANKL), and osteoprotegerin(OPG) were measured in the femur using specific antibodies. The bone mass was analyzed using dual-energy X-ray absorptiometry. In the OVX group, protein expression of OPC was decreased; however, in the ST group, OPC expression was significantly increased when compared with the OVX group. SMO16 significantly reduces RANKL-positive cells in the OVX rat femur. Additionally, SMO16 increased OPG expression levels. Importantly, SMO16 significantly increased bone density. These data suggest that SMO16 increases bone remodeling by regulating OPC, RANKL, and OPG signaling. SMO16 could be a potential alternative treatment for osteoporosis.
참고문헌 (14)
- Osterhoff G, "Bone Mechanical Properties and Changes With Osteoporosis", Injury, 47(2), pp.11~20 (2016)
- Mirza F, "Management of Endocrine Disease : Secondary Osteoporosis : Pathophysiol-ogy and Management", European Journal of Endocrinology, 173(3), pp.131~151 (2015)
- Howe TE, "Exercise for Preventing and Treating Osteoporosis in Postmenopausal Women", Cochrane Database System Review, 6(7) (2011)
- Sunyecz JA, "The Use of Calcium and Vitamin D in the Management of Osteoporosis", Therapeutics and Clinical Risk Management, 4(4), pp.827~836 (2008)
- Bodenner D, "Teriparatide in the Management of Osteoporosis", Clinical In-terventions in Aging, 2(4), pp.499~507 (2007)
- Kearns AE, "Receptor Activator of Nuclear Factor Kappa B Ligand and Os-teoprotegerin Regulation of Bone Remodeling in Health and Disease", Endocrine Review, 29(2), pp.155~192 (2008)
- Kohli SS, "Role of RANKL-RANK", Osteoprotegerin Molecular Complex in Bone Remodel-ing and its Immunopathologic Implications, 2011, pp.15(3), 175~181
- Seo Il-bok, "Effect of SMO16, a KOREAN Poly-Herbal Medicine, on Bone Mass in Ovariectomized Rat", Kinesiology, 2(2), pp.18~22 (2017), J-INSTITUTE
- Cao H, "Effect of Icariin on Fracture Healing in an Ovariectomized Rat Model of Osteoporosis", Experimental and Therapeutic Medicine, 13(5), pp.2399~2404 (2017)
- Bi H, "Key Triggers of Osteoclast-re-lated Diseases and Available Strategies for Targeted Therapies : A Review", Frontiers in Medicine, 20(4), pp.234~ (2017)
- Ikebuchi Y, "Coupling of Bone Resorption and For-mation by RANKL Reverse Signalling", Nature, 561(7722), pp.195~200 (2018)
- Dougall WC, "Rank is Essential for Osteoclast and Lymph Node Develop-ment", Genes & Development, 13(18), pp.2412~2424 (1999)
- Udagawa N, "Osteoprotegerin Produced by Osteoblasts is an Important Reg-ulator in Osteoclast Development and Function", Journal of Endocrinology, 141(9), pp.3478~3484 (2000)
- Bucay N, "Osteoprotegerin-deficient Mice Develop Early Onset Os-teoporosis and Arterial Calcification", Genes & Development, 12(9), pp.1260~1268 (1998)